The DOI matches its Crossref record.
Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
Abstract
Both the hypotension and the sedation elicited by centrally acting antihypertensive agents are traditionally attributed to activation of alpha 2 adrenergic receptors. Second-generation centrally acting agents such as moxonidine are less sedating but retain antihypertensive efficacy. A novel receptor which recognizes imidazolines may contribute to their vasodepressor action in the ventrolateral medulla (VLM). We sought to determine whether moxonidine was a selective ligand for these putative I1-imidazoline receptors in different species and tissues. Moxonidine inhibited [3H]clonidine binding to bovine VLM membranes in a heterogeneous manner, showing 40-fold selectivity for one component. Masking studies using selective inhibitors to block either I1-imidazoline or alpha 2 sites established that the population of sites showing high affinity for moxonidine were I1-imidazoline sites. Moxonidine also showed 70-fold selectivity for I1-imidazoline sites labeled by [125I]p-iodoclonidine in the VLM. Moxonidine competitively inhibited [3H]clonidine binding to I1-imidazoline sites at concentrations that failed to inhibit alpha 2 binding. In the rat renal medulla, moxonidine showed almost 700-fold selectivity for I1-imidazoline sites relative to the alpha 2B receptor subtype. The high affinity of moxonidine for I1 sites was confirmed by using membranes prepared from bovine adrenomedullary cells, which lack alpha 2 adrenergic receptors. Among centrally acting antihypertensives, clinical potency correlated with binding affinity at bovine VLM I1-imidazoline sites (r = 0.996, N = 4), but not with alpha 2 adrenergic affinity (r = -0.239, N = 6). The potent action of moxonidine on I1-imidazoline receptors may account for its antihypertensive efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Agmatine: an Endogenous Clonidine-Displacing Substance in the Brain
Li, G., Regunathan, S., Barrow, C. J., Eshraghi, J., Cooper, R., & Reis, D. J. (1994) · Science · doi:10.1126/science.7906055 · Cited by 738
Moxonidine treatment of hypertensive patients with advanced renal failure
Vonend, O., Marsalek, P., Russ, H., Wulkow, R., Oberhauser, V., & Rump, L. C. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00021 · Cited by 91
Metadata
- Authors
- Ernsberger, P., Damon, T. H., Graff, L. M., Schäfer, S. G., & Christen, M. O.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1993-01
- Volume
- 264
- Issue
- 1
- Pages
- 172-182
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1952790402
- Cited by
- 245
- References
- 0
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. https://app.cochat.ai/papers/10.1016/s0022-3565(25)10249-8
- The paper
- Ernsberger, P., Damon, T. H., Graff, L. M., Schäfer, S. G., & Christen, M. O. (1993). Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(25)10249-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.